secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0000950103-24-000236
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics reports preliminary ZYNLONTA Q4 net sales ~$16.5M; cash ~$278.5M
--------------------------------------------------------------------------------

- Preliminary ZYNLONTA Q4 2023 net sales ~$16.5M, double-digit percentage increase from Q3 2023.
- Cash and cash equivalents ~$278.5M at Q4-end; cash runway extended to Q4 2025 (prev. mid-2025).
- LOTIS-7 combo trial cleared first dosing cohort with no DLT; first 5 evaluable patients all showed response.
- ADCT-601 (AXL) reached MTD; early antitumor activity in monotherapy and combination; dose optimization ongoing.
- Discontinued ADCT-901 (KAAG1) due to limited efficacy; reallocating capital to prioritized pipeline programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010324000236/0000950103-24-000236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010324000236/dp204839_8k-2.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-000236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer